Inventor
TEHRANI LIDA
US16 patents
⚠️ This page may combine multiple inventors who share the name “TEHRANI LIDA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CELGENE CORP
5 patentsUS11634407B2Apr 25, 2023
Cereblon binding compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP5 citations73
US11739075B2Aug 29, 2023
Cereblon binding compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP3 citations71
US11560371B2Jan 24, 2023
Cereblon binding compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP3 citations71
US12227490B2Feb 18, 2025
Cereblon binding compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP0 citations61
US12103920B2Oct 1, 2024
Cereblon binding compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP0 citations61
SIGNAL PHARM LLC
4 patentsUS9771371B2Sep 26, 2017
Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
SIGNAL PHARM LLC4 citations83
US10167290B2Jan 1, 2019
Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
SIGNAL PHARM LLC1 citations72
US11292796B2Apr 5, 2022
Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
SIGNAL PHARM LLC0 citations62
US10683298B2Jun 16, 2020
Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
SIGNAL PHARM LLC0 citations51
PERRIN-NINKOVIC SOPHIE
3 patentsUS8492381B2Jul 23, 2013
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
PERRIN-NINKOVIC SOPHIE44 citations95
US8110578B2Feb 7, 2012
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
PERRIN-NINKOVIC SOPHIE67 citations95
US8507492B2Aug 13, 2013
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway
PERRIN-NINKOVIC SOPHIE22 citations90
SIGNAL PHARMACEUTICAL LLC
3 patentsUS9428509B2Aug 30, 2016
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARMACEUTICAL LLC6 citations81
US9346812B2May 24, 2016
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARMACEUTICAL LLC6 citations81
US9795607B2Oct 24, 2017
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARMACEUTICAL LLC0 citations49